In the current study GIPR and GLP1R agonism additively lowered food intake and body weight confirming previous reports in mice,15 which may at least in part explain the additive reduction of hepatic steatosis upon treatment with both agonists as it lowers the flux of nutrients towards the liver. Here, GLP1R is linked to fatty liver disease.